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Deep vein thrombosis (DVT) is a major cause of cardiovascular death. The sequence of 
events that promote DVT remains obscure, largely as a result of the lack of an appropriate 
rodent model. We describe a novel mouse model of DVT which reproduces a frequent 
trigger and resembles the time course, histological features, and clinical presentation of 
DVT in humans. We demonstrate by intravital two-photon and epifluorescence microscopy 
that blood monocytes and neutrophils crawling along and adhering to the venous endothe-
lium provide the initiating stimulus for DVT development. Using conditional mutants and 
bone marrow chimeras, we show that intravascular activation of the extrinsic pathway of 
coagulation via tissue factor (TF) derived from myeloid leukocytes causes the extensive 
intraluminal fibrin formation characteristic of DVT. We demonstrate that thrombus-resident 
neutrophils are indispensable for subsequent DVT propagation by binding factor XII (FXII) 
and by supporting its activation through the release of neutrophil extracellular traps 
(NETs). Correspondingly, neutropenia, genetic ablation of FXII, or disintegration of NETs 
each confers protection against DVT amplification. Platelets associate with innate immune 
cells via glycoprotein Ib and contribute to DVT progression by promoting leukocyte re-
cruitment and stimulating neutrophil-dependent coagulation. Hence, we identified a cross 
talk between monocytes, neutrophils, and platelets responsible for the initiation and ampli-
fication of DVT and for inducing its unique clinical features.
©  2012  von  Brühl  et  al.  This  article  is  distributed  under  the  terms  of  an   
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six 
months after the publication date (see http://www.rupress.org/terms). After six 
months it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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RESULTS
Flow restriction in mice induces venous thrombosis 
resembling human DVT
Most of our current mechanistic knowledge regarding DVT 
pathophysiology has been gained from mouse models using 
denudation of the venous endothelial surface (Eitzman et al., 
2000; Angelillo-Scherrer et al., 2001; Wang et al., 2006). 
However, unlike in arterial thrombosis, a frequent (though 
not the only) trigger for DVT formation in patients is depres-
sion of venous blood flow without endothelial denudation 
(Sevitt, 1974; Mammen, 1992). To account for this common 
clinical setting leading to DVT in humans, we developed a 
novel mouse model in which venous thrombosis is initiated by 
restriction of blood flow in the absence of endothelial disrup-
tion, as indicated by scanning electron microscopy (Fig. 1 A). 
When we reduced blood flow in the inferior vena cava (IVC) 
by 80% (Fig. 1 B), we detected small thrombi across differ-
ent mouse strains after 6–12 h, whereas completely occlusive 
thrombi developed beyond 24–48 h in 60% of mice (not de-
picted; and Fig. 1, C and D). This protracted time course of 
DVT development closely resembles the dynamics of human 
DVT formation (Warlow et al., 1976). Computed tomogra-
phy revealed DVT in mice with flow restriction, but not in 
sham-operated animals (Fig. 1 C and Video 1), excluding sur-
gical trauma as a trigger. Thrombogenesis was restricted to the 
IVC, whereas systemic thrombus formation was not observed. 
Similar to human VTE, mouse DVT development could be 
prevented by enoxaparin (Fig. 1 D). Mature thrombi revealed 
the characteristic layered morphology reminiscent of thrombi 
in DVT patients with a larger red thrombus and a smaller pro-
portion of white thrombus material (Fig. 1, E and F; Sevitt, 
1974). Together, this suggests that our DVT model closely 
reproduces the time course, histological features, and clinical 
presentation of localized DVT in humans, developing in re-
sponse to reduced venous blood flow.
Innate immune cells are recruited to the vessel wall early 
during DVT formation
Although recent studies have suggested a link between 
inflammation and DVT, the precise role of immune cells   
in DVT development remains unclear (Day et al., 2005; 
Roumen-Klappe et al., 2009). When we examined venous 
thrombi that developed in response to 48 h of flow restric-
tion, inflammatory leukocytes were in fact a major cellular 
constituent. Leukocytes were distributed in clusters or layers 
adjacent to the intact endothelium (Fig. 1 F, Fig. 2 A, and 
Video 2). Ly6Ghi myeloperoxidase (MPO)-expressing neu-
trophils were the predominant leukocyte subset within venous   
thrombi constituting 70% of all accumulated leukocytes, 
whereas Ly6G–F4/80+ monocytes represented the remain-
der, 30% (Fig. 2 A and not depicted). Lymphocytes were 
virtually absent, pointing to the active accumulation of my-
eloid leukocytes in mouse DVT.
We then determined whether accumulation of innate im-
mune cells is a consequence or rather a cause of DVT forma-
tion. Scanning and transmission electron microscopy, as well 
Deep vein thrombosis (DVT) and pulmonary embolism, 
collectively referred to as venous thromboembolism (VTE), 
constitute a leading cause of cardiovascular death (Roger   
et al., 2011). The incidence of VTE increases dramatically 
over 45 yr of age and ranges from 300,000 to more than 
two  million  per  year  in  the  United  States  with  similar   
rates in Europe (Cohen et al., 2007; Heit, 2008; Moll and 
Mackman, 2008). In light of an increasing life expectancy, 
strategies to prevent and treat VTE will become an even 
more important health care issue worldwide (Silverstein   
et al., 1998). Whereas arterial thrombosis is triggered by 
endothelial disruption, a frequent mechanism leading to 
DVT is stasis in the absence of endothelial injury (Sevitt, 
1970; Esmon, 2009). In keeping with this, immobilization 
(e.g., during long-distance flights), pregnancy, and chronic 
venous insufficiency, each major causes of impaired venous 
blood flow, are associated with an increased risk of DVT 
development (Payling Weight et al., 1951; Wright et al., 
1952; Geerts et al., 1994; Hughes et al., 2003; Heit et al., 
2005). However, the molecular and cellular events that trans-
late depressed venous blood flow into thrombogenesis re-
main unknown.
Venous thrombi have a characteristic laminar structure. 
They are rich in fibrin and red blood cells and they are per-
vaded by large numbers of leukocytes (Wakefield et al., 1995). 
There is increasing evidence that inflammatory processes 
and DVT are closely linked. In support of this, C-reactive 
protein, an inflammatory marker, has been shown to be in-
creased in DVT patients. In addition, acute infections pre-
dispose to DVT, further supporting a role of inflammation 
in  thrombosis  (Bucek  et  al.,  2002;  Smeeth  et  al.,  2006). 
Whereas several studies have implicated leukocytes in DVT 
resolution, their role in DVT development, as well as the 
precise contribution of different leukocyte subsets to DVT 
induction, still remains unclear.
In particular, the lack of an appropriate mouse model 
leading to DVT in a large vein without applying endothe-
lial denudation has limited our understanding of the pro-
cesses that support different stages of venous thrombogenesis. 
We therefore established a novel mouse model of DVT in-
duced by flow restriction, closely resembling the kinetics, 
the histological features, and the clinical presentation of 
human DVT in patients with compromised venous blood 
flow. Using this model in combination with state-of-the-
art intravital imaging, we assessed the early cellular events 
that trigger DVT formation. We identified that reduction 
of blood flow induces a proinflammatory endothelial phe-
notype initiating recruitment of innate immune cells, par-
ticularly neutrophils and monocytes. Recruited leukocytes 
start fibrin formation via blood cell–derived tissue factor 
(TF), which, as we show here, is the decisive trigger for the 
massive fibrin deposition characteristic of DVT. Further-
more, platelets are critical for DVT propagation, as they 
support leukocyte accumulation and promote neutrophil 
extracellular trap (NET) formation, which in turn triggers 
FXII-dependent thrombus propagation.JEM Vol. 209, No. 4 
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flow restriction. Within only 1 h of de-
pressed venous blood flow, leukocytes started 
to roll along, adhere, or crawl on the venous 
endothelium (Fig. 3, A–C; and Video 3). In 
contrast, leukocytes barely interacted with 
the endothelium when venous blood flow 
was  left  unperturbed  in  sham-operated 
animals, excluding surgical preparation as trigger of the inflam-
matory response (unpublished data). Leukocyte accumulation 
increased significantly over time, and after 5–6 h leukocytes 
carpeted virtually the entire endothelial surface (Fig. 3, B and C), 
consistent with the ex vivo observations (Fig. 2, B–D). These 
findings clearly suggest that massive leukocyte accumulation 
precedes the development of DVT in response to restriction 
of venous blood flow.
as standard histology, revealed that leukocytes were recruited 
to the IVC in large quantities already after 6 h of flow restric-
tion (Fig. 2, B–D). Leukocytes adhered directly to the luminal 
aspect of the venous endothelium, whereas endothelial dis-
ruption was never detected (Fig. 2, B–D). Next, we per-
formed intravital epifluorescence and two-photon microscopy 
(2P-IVM) to dissect the dynamics of leukocyte recruit-
ment during DVT development in the IVC in response to 
Figure 1.  A novel clinically relevant mouse 
model of DVT. (A) Scanning electron microscopic 
images of the IVC. Images taken immediately after 
(baseline) and 1 h after partial ligation in the IVC 
illustrate the intact endothelial cell lining of the IVC 
without endothelial disruption. Bars, 5 µm. Shown is 
a representative of n = 3 experiments. (B) Assess-
ment of blood flow in the IVC in response to partial 
ligation (n = 16). Dots represent individual experi-
ments; lines show the mean of each group.  
(C) Evaluation of DVT by contrast-enhanced computed 
tomography (CT) 48 h after flow restriction in the 
IVC (also see Video 1). CT images were acquired in a 
sagittal projection using a small animal CT scanner. 
Right: animal with DVT at 48 h after flow restriction. 
The dotted line shows the IVC in the abdominal 
cavity. Arrowheads point to the lack of contrast 
agent, indicating thrombus formation. Left: control 
animal with sham ligation showing continuous 
contrast filling of the IVC. Shown is a representative 
of n = 3 experiments. (D) Weight (milligrams) of 
harvested IVC thrombi 48 h after DVT induction in 
C57BL/6 (n = 6), SV129 mice (n = 4), and after 
enoxaparin treatment (n = 5). Dots represent indi-
vidual experiments; lines show the mean of each 
group. (E) Macroscopic and microscopic assessment 
of venous thrombi after 48 h of flow restriction in 
C57BL/6 animals. Regions of red (R) and white (W) 
thrombus can be distinguished macroscopically 
(left) and microscopically in a longitudinal (middle) 
and cross section (right) stained with van Gieson 
(vG). The thrombus shows the typical white and 
erythrocyte-rich red layers. Bars: (left and middle)  
1 mm; (right) 100 µm. Shown is a representative of 
n = 10 experiments. (F) Excised thrombosed IVC 
obtained 48 h after induction of DVT in C57BL/6 
animals. Regions of red and white thrombus can be 
distinguished microscopically in a longitudinal HE-
stained section. Carstairs staining (CS) is demon-
strating the layers of fibrin, platelets, and red blood 
cells throughout the thrombus, and DAPI staining 
illustrates the distribution of leukocytes in clusters 
(arrow) and layers (arrowhead). Bars, 1 mm. Shown 
is a representative of n = 3 experiments.822 Innate immune cells and platelets initiate DVT | von Brühl et al.
and  Video  4).  We  then  examined  heterozygous 
CX3CR1-eGFP mice to specifically define mono-
cyte recruitment. This revealed that CX3CR1+ 
monocytes constitute 15% of the recruited leuko-
cytes (Fig. 3, D and F; and Video 5). Together, 
these findings indicate that neutrophils and mono-
cytes are the predominant leukocyte subsets that 
actively accumulate at the vascular surface during 
DVT development.
Leukocyte accumulation depends  
on endothelial P-selectin
Subsequently, we evaluated the molecular determi-
nants triggering the accumulation of leukocytes dur-
ing DVT development. Flow restriction resulted in 
up-regulation of mRNA encoding for multiple 
trafficking  molecules,  including  CCL2,  CXCL1, 
CXCL5, and IL-6 (Fig. 4 A). In addition, the endo-
thelium of the restricted IVC was decorated with 
P-selectin and von Willebrand factor (vWF), two ad-
hesive proteins stored in endothelial Weibel Palade 
bodies and mobilized to the endothelial surface upon 
cell activation (Myers et al., 2002). In contrast, P-selectin 
mRNA was only moderately (nonsignificantly) up-
regulated (Fig. 4, B and C). This suggests that in 
response  to  depressed  blood  flow,  the  vessel  wall 
adopts a proinflammatory phenotype with intact but activated 
endothelial cells exposing adhesion molecules on their surfaces. 
We then focused on the role of P-selectin (Fig. 4, B and C). In 
P-selectin–deficient mice (SELP/), leukocyte rolling (not de-
picted) and subsequent adhesion was virtually absent (Fig. 4 D). 
Notably, SELP/ mice were protected against DVT devel-
opment (Fig. 4 E), indicating that recruitment of innate 
immune cells is indispensable for DVT development. Both 
platelets and endothelial cells express P-selectin; however, in-
fusion of WT platelets into SELP/ mice did not rescue 
To dissect the leukocyte subsets recruited in response to 
depressed blood flow, we next induced flow restriction in 
LysM-eGFP reporter mice. We observed that >80% of all 
cells recruited during the first 6 h were eGFPhi (Fig. 3 D). In 
addition to neutrophils, monocytes also express eGFP in 
LysM-eGFP mutants, albeit at lower levels that are beyond 
the detection limit of 2P-IVM (Fig. 3 E). Correspondingly, 
2P-IVM revealed that 90% of all eGFPhi cells recruited 
to venous thrombi also stain positive for Ly6G, indicating that 
eGFPhi cells indeed mainly represent neutrophils (Fig. 3 F 
Figure 2.  Leukocytes are recruited during the early 
phase of venous thrombosis to the intact endothelial sur-
face. (A) Leukocyte accumulation in DVT induced by 48 h of 
flow restriction. vG (top left) and immunohistochemical stain-
ings (middle and right, top and bottom) for Ly6G+ MPO+ neu-
trophils and F4/80+ monocytes. Nuclei are counterstained with 
DAPI. Bars, 50 µm. The bottom left shows the quantification of 
neutrophils and monocytes. Results are mean ± SEM (n = 3). 
(B) Scanning electron microscopic images taken directly after 
partial IVC ligation showing the intact endothelium. After 6 h, 
a carpet composed of cell aggregates and fibrin can be visual-
ized on the endothelial surface. Bars, 5 µm. (C) TEM images of 
venous vessels showing the anticoagulant endothelial cell 
lining (pseudocolored in yellow). Bar, 5 µm. Detail is shown in 
the right image. (D) Histological analyses of the IVC 6 h after 
flow reduction examining leukocyte recruitment in the early 
phase of venous thrombus formation. Histological sections in 
three different stainings (HE, vG, and MSB). Bars: (top row)  
20 µm; (bottom row) 10 µm. Data are representative of  
n = 3 experiments per group.JEM Vol. 209, No. 4 
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Figure 3.  Neutrophils and monocytes 
are the main leukocyte subsets accumu-
lating during the initiation of DVT.  
(A) Neutrophils (green) crawling on the 
vessel wall (red) of the IVC 2 h after DVT 
induction visualized by two-photon micros-
copy. Tracks of individual neutrophils are 
shown in white (also see Video 3). Bar, 50 µm. 
Shown is a representative of n = 3 experi-
ments. (B) Time course of early leukocyte–
endothelial interaction within 6 h of  
flow restriction as evaluated by intravital 
microscopy in WT animals using Acridine 
orange (WT + acr orange). Baseline images 
were taken before ligation. LysM-eGFP mice 
were used to evaluate neutrophils and 
CX3CR1-eGFP mice were analyzed to evalu-
ate monocytes. Bars, 100 µm. Shown is a 
representative of n = 5 experiments.  
(C) Dynamics of the recruitment of distinct 
subsets of innate immune cells during DVT 
initiation determined in vivo by video micros-
copy. Rolling and firm adhesion of leu-
kocytes are given as number per square 
millimeter. Results are shown as mean ± 
SEM (n = 5 per group). (D, Left) Relative 
frequency of neutrophils and monocytes at 
6 h of flow restriction as assessed by intra-
vital video microscopy. Results are mean ± 
SEM (n = 5 per group). (D, Right) Represen-
tative images taken by intravital epifluores-
cence microscopy showing blood cell 
recruitment 6 h after flow restriction in the 
IVC. Neutrophils were visualized in LysM-eGFP 
mice. The number of recruited monocytes 
was assessed using CX3CR1-eGFP mice.  
In both strains of mice, all leukocytes  
(irrespective of their lineage) were identified 
by counterstaining with the fluorescent dye 
Acridine orange (pseudocolored in red). 
Bars, 100 µm. (E) FACS analysis of blood in 
LysM-eGFP and CX3CR1-eGFP mice without 
IVC ligation using a neutrophil specific anti-
Ly6G antibody. (F) Intravital two-photon 
microscopy of LysM-eGFP and CX3CR1-
eGFP with PE-labeled anti-Ly6G antibody  
6 h after DVT induction (left). Bars, 50 µm. 
Quantification of Ly6G+ GFP+ double- 
positive cells in these mouse strains (right; 
 Videos 4 and 5). Shown is a representative 
of n = 3 experiments.
leukocyte recruitment or thrombus formation (Fig. 4 F). Hence, 
predominantly endothelial P-selectin contributes to leukocyte 
recruitment and DVT formation in response to flow restric-
tion, whereas platelet P-selectin appears to be less important.
Blood cell–derived TF is a central initiator of DVT
Next, we investigated how innate immune cells initiate 
DVT development. Activation of blood coagulation is likely 
to play a central role in our model, as enoxaparin efficiently 
prevented thrombus formation (Fig. 1 D). Because TF is the 
major initiator of coagulation and because different leuko-
cytes express TF (Furie and Furie, 2007; Manly et al., 2011), 
we investigated the participation of blood cell–derived TF 
in DVT development. To examine the overall role of TF,   
we compared transgenic mice that express no mouse TF and 
only minimal (<1%) 
amounts  of  human 
TF  (low-hTF)  with 
mice expressing nor-
mal levels of human 
TF (HCV; Pawlinski 
et al., 2007). In HCV 
mice, flow restriction resulted in robust fibrin deposition 
within 6 h. In contrast, fibrin formation was completely 
abolished in low-hTF mice and DVT development was never 
observed (Fig. 5, A and B). Hence, TF-driven coagulation is 
indispensable for thrombus formation in response to flow 
restriction. Notably, loss of TF did not affect leukocyte re-
cruitment, indicating that coagulation is not required to es-
tablish the inflammatory response during DVT (Fig. 5 C).824 Innate immune cells and platelets initiate DVT | von Brühl et al.
formation was significantly attenuated 
compared with WT animals, confirm-
ing the major role of myeloid blood 
cell–derived TF for DVT development 
(Fig. 5 D). The procoagulant activity 
of myeloid cells isolated from LysMCre-
TFflox/flox mice is significantly reduced, 
yet not fully inhibited (Pawlinski et al., 
2010). This is likely to explain the different degrees of protection 
from DVT observed in LysMCre-TFflox/flox mice as compared with 
low-hTF chimeras. Predominantly, Ly6G monocytes and, to a 
lesser extent, Ly6G+ neutrophils expressed TF in venous thrombi 
(Fig. 5 E), suggesting that both subsets, particularly monocytes, 
contribute to TF-driven coagulation during mouse DVT.
Neutrophils promote propagation of DVT via NET formation
Given  their  frequency  among  leukocytes  recruited  to  the 
IVC, we next examined the contribution of neutrophils to 
DVT development in more detail. To address this, we de-
pleted neutrophils by injection of an anti-Ly6G antibody and 
To define the source of TF and to differentiate whether TF 
expressed by blood cells or by the vessel wall contributes to DVT 
development, we next analyzed HCV mice that had been trans-
planted with low-hTF bone marrow cells. None of these chime-
ras developed DVT within 48 h of flow restriction (Fig. 5 B). 
This indicates that hematopoietic TF, but not vessel wall TF, is 
responsible for initiation of DVT in response to depressed venous 
blood flow without overt vessel damage. To specifically evalu-
ate the participation of TF expressed by myeloid leukocytes, 
we analyzed mice with a deletion of TF in myeloid leukocytes 
(LysMCre-TFflox/flox  mice),  including  both  monocytes  and 
neutrophils (Pawlinski et al., 2010). In these mice, thrombus 
Figure 4.  Crucial role of P-selectin for 
leukocyte accumulation in DVT. (A) RT-PCR 
of trafficking molecules in the IVC in response 
to flow restriction at baseline or 6 and 48 h 
after DVT induction (n = 5 per group). Results 
are shown as mean ± standard deviation.  
(B) RT-PCR of P-selectin in the IVC at  
baseline or 6 and 48 h after DVT induction  
(n = 5 per group). Results are shown as mean ± 
standard deviation. (C) Representative 
immunohistochemical stainings of the IVC 
endothelium 48 h after DVT induction show-
ing P-selectin and vWF on the endothelial 
surface. Nuclei are counterstained with DAPI. 
Bars, 50 µm. (D, Left) Representative in vivo 
images of adherent leukocytes in C57BL/6 
and SELP/ mice 6 h after induction of DVT. 
Leukocytes were stained with Acridine  
orange and visualized by intravital video 
microscopy (arrowhead indicates aggregates; 
arrows indicate single adherent cells).  
Bars, 100 µm. (D, Right) Quantitative analysis 
of firm leukocyte adhesion, 6 h after flow 
restriction. Firm cell adhesion is given in 
number per square millimeters of C57BL/6  
(n = 5) and SELP/ (n = 7). Data are shown 
as mean ± SEM. (E, Left) Representative 
images of the excised IVC including the 
thrombus after 48 h in C57BL/6 and SELP/ 
mice. Bars, 1 mm. (E, Right) Thrombus weight 
in C57BL/6 (n = 8) and SELP/ mice (n = 4) 
48 h after DVT induction. Dots represent 
individual experiments; lines show the mean 
of each group. (F) Histological analysis of the 
harvested IVC thrombi 48 h after flow reduc-
tion given as thrombus load in square mil-
limeters (n = 5). plt, platelets. Data are shown 
as mean ± SEM.JEM Vol. 209, No. 4 
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apart from acting as a potential source 
of  myeloid  TF,  neutrophils  deliver 
additional  signals  supporting  venous 
thrombogenesis. Recently, activated neu-
trophils  have  been  shown  to  release 
NETs, which consist of extracellular 
chromatin fibers with a backbone of 
histones (Brinkmann et al., 2004) and 
which may exert prothrombotic effects 
in vitro. Although release of NETs has 
been previously observed in a baboon 
model of venous thrombosis and in sepsis-induced micro-
circulatory thrombosis (Clark et al., 2007; Fuchs et al., 2010), 
the functional consequences of NETosis and their in vivo 
relevance  for  thrombogenesis  in  large  veins  remain  unad-
dressed. Hence, we investigated here whether neutrophils 
might contribute to thrombus formation via release of NETs 
(Brinkmann et al., 2004). In fact, after 3 h of flow restriction, 
we found large amounts of intravascular extracellular DNA 
induced flow restriction in the IVC (Fig. 6 A and not depicted). 
To our surprise, neutropenic mice developed no or signifi-
cantly smaller thrombi compared with isotype-treated con-
trols within 48 h of flow restriction (Fig. 6 B). This suggests 
that monocytes and monocyte-derived TF cannot fully com-
pensate for a loss of neutrophils during DVT.
Because TF expression by Ly6G+ neutrophils was weak 
compared with monocytes (Fig. 5 E), it seemed likely that, 
Figure 5.  Blood cell TF is indispensable for 
venous thrombosis. (A) Fibrin formation during 
DVT development was measured in vivo by in-
travital microscopy in control HCV and low-hTF 
mice using an Alexa Fluor 488–labeled specific 
fibrin antibody. Measurements were performed 
after 1–6 h of flow restriction. Representative 
images acquired by intravital microscopy of  
the IVC are shown on the right (fibrin pseudo-
colored in yellow). Bars, 100 µm. n = 3 per group. 
Data are shown as mean ± SEM. (B) Thrombus 
load was assessed on vG-stained serial sections 
in low-hTF (n = 10) and HCV mice (n = 5), as 
well as in bone marrow chimeras lacking blood 
cell TF (n = 6). Thrombus load is given as square 
millimeters. Dots represent individual experi-
ments; lines show the mean of each group.  
(C) Assessment of leukocyte recruitment 6 h 
after flow reduction by intravital microscopy. 
Leukocytes were visualized using i.v. application 
of the fluorescent dye rhodamine 6G (pseudo-
colored in green). The number of adherent cells 
is given as number per square millimeters (n = 3  
per group). Representative in vivo images are 
shown on the right. Bar, 100 µm. Data are 
shown as mean ± SEM. (D) Thrombus weight (at 
48 h) in control mice (n = 10) and in conditional 
mutants (LysMCre-TFflox/flox) lacking TF in LysM+ 
myeloid cells (n = 12). Dots represent individual 
experiments; lines show the mean of each 
group. (E) Immunohistochemical detection of  
TF protein (red) on Ly6G-positive (green) and  
-negative cells in thrombi at 48 h of flow restric-
tion, indicating TF expression on neutrophils 
(yellow; TF+ and Ly6G+) and monocytes (red;  
TF+ and Ly6G). LysMCre-TFflox/flox mice (bottom) 
were used as negative control. Nuclei are 
stained with DAPI. Bars, 100 µm. Shown is a 
representative of n = 3 experiments.826 Innate immune cells and platelets initiate DVT | von Brühl et al.
whether NETs con-
centrate  prothrom-
botic factors on their 
surfaces. In fact, the 
NETs were decorated with TF and protein disulfide isom-
erase, an enzyme implicated in the activation of blood cell–
derived TF, supporting the concept that they might act as a 
prothrombotic surface (not depicted; Reinhardt et al., 2008). 
Hence, we next examined the functional relevance of NETs 
for DVT formation and treated mice with DNase1. Ad-
ministration of DNase1 reduced NETs and at the same time 
significantly suppressed DVT growth (Fig. 6, G and H). 
revealing a typical NET morphology (Fig. 6 C and Video 6). 
Intravital 2-PIVM revealed that extracellular DNA originates 
from Ly6G+ neutrophils (Fig. 6 D and Video 7). Extracel-
lular DNA was located in close proximity to neutrophils and 
stained positive for the neutrophil granule proteins MPO, 
neutrophil elastase (NE), and the histone proteins H2A-H2B 
and H3, confirming that these structures were NETs (Fig. 6 E 
and not depicted). NETs were virtually absent in neutro-
penic mice, indicating that neutrophils are the major source 
of NETs during DVT development (Fig. 6 F).
Because platelets and a dense network of fibrin/fibrin-
ogen surrounded the NETs, we analyzed in more detail 
Figure 6.  NETs propagate DVT in vivo.  
(A) Leukocyte accumulation in vivo at 6 h of 
flow restriction in the IVC of LysM-eGFP mice 
treated with control antibody or the anti-
Ly6G mAb to deplete neutrophils. Arrowhead: 
aggregated neutrophils; arrows: single, adher-
ent cells. Bars, 100 µm. (B) Thrombus weight 
48 h after DVT induction in isotype and anti-
Ly6G–treated WT mice (n = 6 per group). Dots 
represent individual experiments; lines show 
the mean of each group. (C) Representative 
image of n = 3 experiments of intravital micros-
copy 3 or 48 h after flow reduction showing 
Sytox Green+ NETs in the IVC. Bars, 50 µm.  
(D) Visualization of NETs in vivo by 2-photon 
microscopy. Ly6G-positive neutrophils (green, 
FITC anti-Ly6G antibody) attached to the ves-
sel wall (blue) release Sytox orange–positive 
(red) NET structures inside the IVC 4 h after 
flow reduction (also see Video 7). Sytox  
orange–positive nuclei correspond to dying 
neutrophils, which have not (yet) exposed 
their DNA to the extracellular space. Arrow-
head: extracellular DNA; arrow: neutrophil. 
Bar, 50 µm. (E) Immunohistochemical visual-
ization of NETs by staining for DNA (Hoechst), 
MPO, NE, and histones (H2A-H2B-DNA, H3) in 
the IVC of WT mice 48 h after induction of 
DVT. Hoechst+ DNA originating from MPO+NE+  
neutrophils (arrows) could be detected.  
Arrows, nuclei; arrowheads, NET fibers.  
Bars, 10 µm. (F) Number of NETs in neutrope-
nic mice were quantified in thrombi after 
treatment with anti-Ly6G and isotype control 
antibody (n = 3 per group). Data are shown as 
mean ± SEM. (G) Representative images of WT 
thrombi stained with Hoechst after DNase1 
treatment. Arrowhead, NET fiber. Bars, 10 µm. 
Shown is a representative of n = 3 experi-
ments. (H) After injection of DNase1, throm-
bus weight (left) in the IVC was determined 
after 48 h of flow restriction. Dots represent 
individual experiments; lines show the mean 
of each group. Quantification of NETs is also 
shown (right) as mean ± SEM. Data were ob-
tained in WT injected with normal saline i.v.  
(n = 14) or DNase1 (n = 6). (I) Quantification 
of NETs at 48 h in the enoxaparin-treated 
animals (n = 4 per group). Data are shown as 
mean ± SEM.JEM Vol. 209, No. 4 
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degradation of NETs in vitro (Fuchs et al., 2010), reduced 
the formation of NETs during DVT in vivo (Fig. 6 I), an 
effect which might add to the antithrombotic actions of 
the drug.
Together, these findings indicate that NETs are no inno-
cent bystanders but rather contribute to neutrophil-driven 
coagulation during DVT propagation. Heparin, which has 
a high affinity for histones (Pal et al., 1983) and fosters 
Figure 7.  Platelet recruitment supports DVT formation in vivo. (A) Immunohistological cross sections of the IVC 48 h after DVT induction display plate-
let accumulation (CD41+) within the thrombus. Nuclei are counterstained with DAPI. Bars, 200 µm. Representative of n = 3 experiments. (B) Representative 
images of intravital video microscopy of blood cell recruitment taken at 6 h after DVT induction. Arrowheads: thrombi; arrows: single, adherent cells. Platelets, 
red (rhodamine B); leukocytes, green (Acridine orange). Bars, 100 µm. (C) Time-lapse images of the developing thrombus (arrowheads) visualized by two-
photon microscopy 6 h after DVT induction. Platelets (yellow) and neutrophils (green) are recruited from the bloodstream (blue) to the vessel wall (red; see 
also Video 8). (D) Platelet–leukocyte interaction was determined by intravital microscopy in C57BL/6 and IL4-R/Iba mice after 6 h of flow restriction. Bars: 
(left) 50 µm; (right) 100 µm. The right panel shows quantification of colocalization of leukocytes and platelets in WT (n = 5) and IL4-R/Iba mice (n = 4). Data 
are shown as mean ± SEM. (E) Representative images obtained by video microscopy 6 h after DVT induction in IL4-R/Iba and control animals (n = 3 per 
group). Platelets are pseudocolored in red (DyLight488-labeled GPIb antibody) and leukocytes in green (Acridine orange). Bars, 100 µm. (F) Representative 
images taken by intravital microscopy of WT mice 1 h after induction of venous (left) and 5 min after arterial (right) thrombosis. Arrows show platelet aggre-
gate formation. Leukocytes are fluorescently labeled (green) by i.v. application of Acridine orange. Bars, 50 µm. (G) Quantitative analysis of platelet (plt) and 
leukocyte (lcs) accumulation (as percentage of WT controls) in IL4-R/Iba (n = 3) and WT mice (n = 5). Data are shown as mean ± SEM. (H) Thrombus weight at 
48 h after DVT induction in C57BL/6 (n = 8) and IL4-R/Iba mice (n = 5). Dots represent individual experiments; lines show the mean of each group.828 Innate immune cells and platelets initiate DVT | von Brühl et al.
revealed that most platelets adhered either directly to the 
intact endothelium or were attached to adherent leuko-
cytes (Fig. 7 C and Videos 8–10). Platelets and leukocytes 
formed heterotypic aggregates (Fig. 7, B–D). Considering 
that only 10% of the circulating platelets are labeled in our 
Platelets support DVT formation
In addition to leukocytes, platelets are recruited during DVT 
formation (Fig. 7 A). Intravital microscopy indicated that platelet 
adhesion occurred within 2 h of flow restriction and increased 
over time (not depicted and Fig. 7 B). After 6 h, 2P-IVM 
Figure 8.  Platelets induce NET formation, which triggers FXIIa-dependent thrombus propagation. (A) Freshly isolated human neutrophils were 
incubated with platelet supernatant. Cells were stained with a primary antibody directed against DNA–histone complexes and DAPI and visualized by con-
focal microscopy. Incubation with DNase1 where indicated. Bars, 50 µm. Arrowheads, cell nucleus; arrows, NET. (B) The total number of NETs (left) and NETs 
per leukocyte (right) was quantified on cross sections of thrombi 48 h after flow restriction in IL4-R/Iba mice and WT animals (n = 3 per group). Data are 
shown as mean ± SEM. (C) Analysis of thrombus formation (milligrams) in the IVC of C57BL/6 (n = 9), FXII/ deficient (n = 7), and FXI/ deficient mice  
(n = 7) 48 h after flow reduction. Dots represent individual experiments; lines show the mean of each group. (D) Quantification of fibrin density as percent-
age of fibrin-covered area in the IVC thrombus (n = 4 per group). Data are shown as mean ± SEM. (E) The effects of co-incubation of activated platelets (P) 
and neutrophils (N) on FXII activation in vitro. NETosis was inhibited by an antibody directed against the H2A–H2B–DNA complex. Data are shown as  
mean ± SEM. (F) Confocal visualization of FXII on NETs, released from isolated human neutrophils. Arrow, FXII bound to Sytox Green+ NETs. Bars, 10 µm.JEM Vol. 209, No. 4 
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FXII (Fig. 8 C). In contrast, thrombus weight was only mod-
erately (nonsignificantly) reduced in FXI-deficient mice, in-
dicating that the ability of FXIIa to propagate DVT is largely 
independent of FXI activation. As FXIIa can enhance the 
density of fibrin networks without stimulating thrombin 
generation via FXIa (Konings et al., 2011), we measured the 
density of fibrin deposition in thrombi of FXII-deficient mice. 
The percentage of fibrin-covered area in thrombi of FXII-
deficient mice was decreased compared with WT (Fig. 8 D), 
suggesting that FXIIa might indeed amplify DVT by inter-
acting directly with fibrin.
To further substantiate this concept, we examined in vitro 
whether FXII is activated in response to platelet-dependent 
NET formation. Activated neutrophils alone were able to 
trigger FXII activation (Fig. 8 E, left). This did not involve 
NETs because it remained unaffected by the anti–H2A-H2B 
antibody (Fig. 8 E, right). In the presence of activated plate-
lets, the capacity of neutrophils to trigger FXII activation 
was significantly increased, suggesting an additive effect of 
neutrophils and platelets (Fig. 8 E, left). The anti–H2A-H2B 
antibody completely abolished the effect of platelets on FXIIa 
formation by neutrophils, suggesting that platelet-driven aug-
mentation of neutrophil FXIIa formation requires the pres-
ence of NETs (Fig. 8 E, middle). When we analyzed NETs 
by confocal microscopy, we found that they were decorated 
with FXII (Fig. 8 F). Collectively, these findings suggest that 
NETs are able to bind FXII on their surfaces and provide a 
scaffold for FXII activation, presumably by facilitating auto-
activation of FXII via their negatively charged extracellular 
DNA surfaces. Hence, NET-driven FXII activation is of 
major relevance for propagation of intravascular thrombus 
formation during DVT.
DISCUSSION
The sequence of events that trigger large vein thrombosis in 
response to stasis has remained poorly defined. Using a novel 
mouse model of flow restriction-induced DVT, we have un-
covered the mechanisms underlying the previously proposed 
link between thrombosis and inflammation crucial for the 
pathogenesis of DVT. By two-photon microscopy, we show 
that flow restriction triggers the rapid accumulation of neu-
trophils and monocytes, which is indispensable for DVT 
development. Innate immune cells initiate local fibrin forma-
tion predominantly through delivery of TF. In addition, 
neutrophils form NETs, triggering FXII-dependent coagula-
tion. Although TF appears to be required to initiate DVT, 
neutrophil-driven coagulation contributes to DVT propaga-
tion. Platelets foster leukocyte accumulation and support fibrin 
formation by enhancing neutrophil-dependent coagulation. 
Hence, by combining a novel DVT model with in vivo imag-
ing we have uncovered different processes responsible for the 
emergence of localized thrombosis in response to reduced 
venous blood flow, an important trigger of DVT in humans.
The cellular events initiating DVT during compromised 
venous blood flow remained unclear, mostly as a result of 
the lack of an appropriate rodent model. Previous studies 
model, we estimated that on average each adherent leukocyte 
carries at least one platelet (Fig. 7, B–D). Platelet–leukocyte 
interactions depended on the platelet vWF-receptor glyco-
protein (GP) Ib. Correspondingly, the interaction of plate-
lets and leukocytes was virtually abrogated in IL4-R/Iba 
mice, lacking the external GPIb domain (Fig. 7 D).
To evaluate the quantitative contribution of platelets 
to the cellular content of the thrombus, we stained 100% of 
platelets by injecting a fluorescently labeled anti-GPIb anti-
body, which does not interfere with platelet adhesion and 
aggregation. After 6 h of flow reduction, platelets were dif-
fusely distributed as individual cells across the thrombus and 
formed small aggregates. However, the number of recruited 
leukocytes clearly outnumbered platelet accumulation (Fig. 7 E). 
In contrast to arterial thrombosis, where platelets accumulate 
within minutes and form large aggregates (Massberg et al., 
2010), platelets were mainly recruited as individual cells after 
several hours in venous thrombosis and formed only very few 
small aggregates (Fig. 7, E and F). This suggests that homo-
typic platelet aggregation does not play a crucial role for the 
initiation of venous thrombus formation.
The  platelet  vWF  receptor  GPIb  was  important  for 
overall platelet recruitment and DVT progression, as both were 
markedly reduced in IL4-R/Iba mice (Fig. 7, G and H; and 
not depicted). Likewise, venous thrombus formation was 
significantly  reduced  in  platelet-depleted  mice  (by  95% 
compared with controls, n = 6–8; P < 0.001).
Because GPIb-dependent platelet–leukocyte interactions 
were a prominent phenomenon in venous thrombi (Fig. 7, 
B–D), we addressed whether platelets support DVT develop-
ment by fostering neutrophil-dependent coagulation. In fact, 
leukocyte accumulation was markedly decreased in IL4-R/Iba 
mice (Fig. 7, E and G), suggesting that platelets promote 
leukocyte recruitment. In addition, platelets also supported 
NETosis  as  NETs  were  rapidly  released  from  neutrophils 
when we incubated them with activated platelets in vitro 
(Massberg et al., 2010; Fig. 8 A). This was confirmed by our 
in vivo experiments, as the number of NETs released per re-
cruited leukocyte was significantly attenuated in IL4-R/Iba 
mice (Fig. 8 B). Hence, the GPIb-dependent interaction of 
platelets with leukocytes exerts a dual function during DVT 
development: (1) it supports leukocyte recruitment; and (2) it 
stimulates NET formation by neutrophils.
Neutrophils amplify DVT by initiating  
FXII-dependent coagulation
Finally, we asked how the interplay of platelets and netting 
neutrophils might contribute to venous thrombogenesis, 
which is critically dependent on activation of the coagulation 
system. Negatively charged surfaces can trigger activation 
of FXII, the initiator of the intrinsic coagulation pathway. 
Because NETs are negatively charged, we hypothesized that 
NETs could potentially activate FXII during DVT (e.g., via 
their polyanionic DNA components). In fact, we found that 
thrombus formation is significantly reduced after injection 
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(Day et al., 2005; Zhou et al., 2009). Here, we report that 
blood cell–derived TF, and not vessel wall TF, critically con-
tributes to venous thrombosis, which could be explained by 
two factors: (1) we did not completely abrogate venous blood 
flow allowing a continuous accumulation of leukocytes dur-
ing DVT initiation; and (2) endothelial denudation was absent 
in our model, limiting the contribution of vessel wall–derived 
TF. Mice lacking TF in the myeloid blood cell lineage were 
protected from DVT development, demonstrating that blood 
cell TF is mainly delivered by this cell type. Because LysM is 
active in both neutrophils and monocyte subsets, the LysMCre-
TFflox/flox strain used in our experiments does not allow dif-
ferentiation of the relative contribution of neutrophil or 
monocytes to the local delivery of blood cell–derived TF. 
However, two of our findings favor monocytes as a major 
source of TF in our DVT model: (1) we found that TF ex-
pression by Ly6G+ neutrophils was weak, whereas monocytes 
revealed a strong TF signal; and (2) we observed that neutro-
phils contribute to DVT in a process involving NET forma-
tion and FXII activation and that inhibition of these pathways 
significantly attenuates DVT formation. This suggests that 
NET formation and FXII activation, rather than delivery of 
TF, are the predominant neutrophil-dependent contributions 
to thrombogenesis in our DVT model. Nevertheless, we can-
not rule out that neutrophil-derived TF also contributes to 
DVT progression in this model.
Consistent with other models, we observed that neutro-
phils constitute the predominant leukocyte subset recruited 
to the site of DVT (Stewart et al., 1974; Zhou et al., 2009; 
Diaz et al., 2010). Although neutrophils have previously been 
involved  in  postthrombotic  remodeling  of  the  vein  wall 
(Varma et al., 2003), their contribution to venous thrombus 
formation has remained unclear. Here, we show that neutro-
phil depletion results in a profound inhibition of DVT devel-
opment. Neutrophils recruited to the IVC wall generate NETs, 
which are known to act as prothrombotic scaffolds by bind-
ing vWF, degrading potent anticoagulants like TF pathway 
inhibitor, and reducing thrombomodulin-dependent protein 
C activation (Ward et al., 1997; Fuchs et al., 2010; Massberg 
et al., 2010; Ammollo et al., 2011). Although NETs have 
been found in baboon DVT (Fuchs et al., 2010), their func-
tional significance for venous thrombogenesis remained un-
clear. Here, we report that inhibition of NETosis resulted 
in an attenuated DVT progression. We show that activated 
platelets bind to neutrophils in a process involving GPIb. This 
interaction fosters NET formation, as has been reported by 
others previously (Clark et al., 2007). NETs, in turn, act as a 
procoagulant surface propagating DVT development through 
the binding and activation of FXII. Hence, our present study 
provides direct in vivo evidence that NETs represent an im-
portant mechanistic link between neutrophil-driven venous 
inflammation and venous thrombogenesis. Interestingly, gen-
eration of NETs has recently been reported in disease states 
known to be linked with an increased risk of thrombotic dis-
orders, such as systemic lupus erythematosus (Garcia-Romo 
et al., 2011). However, future studies will have to address 
performed in mice predominantly used endothelial injury to 
induce DVT (Eitzman et al., 2000; Angelillo-Scherrer et al., 
2001; Wang et al., 2006). However, exposure of subendo-
thelial matrix is a rare cause of DVT in humans (Sevitt, 1974; 
Mackman, 2008), suggesting that findings obtained from 
models that use endothelial disruption as a thrombogenic 
stimulus may have limited relevance for the clinical setting 
(Sevitt, 1974; Mackman, 2008). Here, we therefore estab-
lished a novel mouse model in which venous thrombosis is 
initiated by depression of venous blood flow in the absence 
of endothelial disruption. Several aspects indicate that our 
model closely resembles DVT formation in humans. First, 
perturbation, but not complete cessation, of venous blood 
flow is a common trigger, though not the only trigger of 
DVT formation in patients. Second, similar to the time course 
in humans (Warlow et al., 1976), DVT developed over a 
prolonged period of time (12–48 h). Third, the layered 
multicellular  structure  of  the  thrombi  is  reminiscent  of 
human venous thrombi (Sevitt, 1974). Fourth, enoxaparin, 
the  standard  prophylactic  strategy  in  human  patients,  also 
prevented venous thrombosis in our model. Although our 
approach does not account for other triggers of venous 
thrombogenesis, including malignancies, sepsis, or hereditary 
disorders, the DVT model presented here will be valuable for 
evaluation of new drugs implicated in prophylaxis and treat-
ment of DVT in the large group of human patients, in which 
compromised venous blood flow is the major mechanism of 
DVT formation.
By combining this novel model with state-of-the-art in-
travital imaging, we defined the subsets of blood cells re-
cruited to the vessel wall within the first hours of depressed 
venous blood flow. We observed that P-selectin–dependent 
neutrophil and monocyte recruitment is critical for DVT for-
mation. Although the exact triggers of P-selectin exposure 
remain unclear, hypoxia and changes in shear forces are likely 
mechanisms.  Recently,  soluble  P-selectin  has  been  estab-
lished as a diagnostic marker for DVT, supporting a clinical 
role of this adhesion molecule (Ramacciotti et al., 2011). In 
addition, several chemokines were up-regulated in the venous 
vessel wall in response to flow restriction. Together, this sup-
ports a critical role of sterile inflammation in venous throm-
bogenesis, consistent with the clinical observation of increased 
levels of inflammatory biomarkers, such as CRP, in human 
DVT patients (Bucek et al., 2002).
But how do innate immune cells trigger DVT? In view of 
the extensive intravascular fibrin formation typical for DVT, 
it is generally assumed that the coagulation system plays a 
critical role for venous thrombosis. Nevertheless, the mecha-
nisms that drive fibrin formation remained largely unclear. 
We have identified innate immune cells as the primary initia-
tors of clot formation contributing to DVT by two distinct 
mechanisms: (1) through delivery of TF; and (2) by release of 
procoagulant NETs.
Earlier studies applying endothelial disruption or complete 
IVC occlusion suggested that thrombus formation in the venous 
vasculature is primarily driven by TF from the vessel wall JEM Vol. 209, No. 4 
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specifically targeting the cellular factors that initiate DVT de-
velopment. Such a strategy might improve the benefit-to-risk 
profile of anticoagulant therapy in comparison with non-
specific inhibition of the final common coagulation pathway 
that is characteristic of current therapies.
MATERIALS AND METHODS
Animals. Specific pathogen-free WT C57BL/6J, SV129S1, and B6.129s7-
Selp/J mice were obtained from Charles River. IL4R/GPIb-tg (IL4-R/
Iba) mice were generated as previously described (Kanaji et al., 2002). For 
intravital visualization, heterozygous CX3CR1eGFP/+ and LysMeGFP/+ knockin 
mice were used (Faust et al., 2000; Jung et al., 2000). CX3CR1eGFP/+ mice 
were provided by S. Jung (Weizmann Institute of Science, Department of 
Immunology, Rehovot, Israel). LysMeGFP/+ knockin mice were provided 
by T. Graf (Center of Genomic Regulation, Barcelona, Spain). HCV, Low-
hTF, LysMCre, and TFflox/flox mice were maintained on the C57BL/6J back-
ground (Parry et al., 1998; Clausen et al., 1999; Pawlinski et al., 2007). 
LysMCre-TFfl/fl animals were generated by crossing LysMCre with TFflox/flox mice 
as previously described (Pawlinski et al., 2010). FXII- and FXI-deficient 
mice were generated as previously described (Gailani et al., 1997; Pauer et al., 
2004) and provided by J. Heesemann (Max von Pettenkofer-Insitut, Klinikum 
Innenstadt, Ludwig-Maximilians-Universität München, Munich, Germany). 
All mice used in the experiments were 8–14 wk old and weight and sex 
matched. All procedures performed on mice were approved by the local leg-
islation on protection of animals (Regierung von Oberbayern, Munich) and 
the  Immune  Disease  Institute’s  Animal  Care  and  Use  Committee  (IDI 
4M0109/HMS04564).
Mouse model of flow restriction in the IVC. Mice were anesthetized 
by intraperitoneal injection as described previously (Massberg et al., 2002). 
A median laparotomy was performed and the IVC was exposed by atrau-
matic surgery. We positioned a space holder (FloppyR II Guide Wire 0.014 
in [0.36 mm]; Guidant Corporation) on the outside of the vessel and we 
placed a permanent narrowing ligature (8.0 monofil polypropylene filament, 
Premilene; Braun) exactly below the left renal vein. Subsequently, the wire 
was removed to avoid complete vessel occlusion. Side branches were not 
ligated or manipulated. Flow velocity was determined immediately after the 
flow restriction (Cap-Image 7.1). Because we wanted to rule out endothelial 
injury as a trigger for venous thrombosis, all mice with bleedings or any 
injury of the IVC during surgery were excluded from further analysis. There 
was no difference in the exclusion rate across the different experimental 
groups. After the procedure, a subset of animals was investigated by intravital 
microscopy. In the remainder, the median laparotomy was immediately 
sutured by a 7.0 polypropylene suture (Ethicon). For weight measurement, the 
vessel was excised just below the renal veins and proximal to the confluence 
of the common iliac veins. After the restriction procedure the blood flow 
velocity was reduced by 80% (Fig. 1 B). The shear stress was 0.144 dyne/cm2 
± 0.02 SEM before the flow restriction and 0.072 dyne/cm2 ± 0.017 SEM 
after the procedure in the IVC close to the site of ligation. Sham experiments 
consisted of preparation of the IVC and placement of the filament under the 
vessel without ligation.
In vivo model of arterial thrombosis by carotid artery ligation. As a 
model of arterial thrombosis, carotid injury was induced as previously 
described (Massberg et al., 2010).
Preparation of platelets and leukocytes for intravital microscopy. 
Murine platelets were isolated from whole blood and labeled with 5-carboxy-
flourescein diacetate succinimidyl ester (DCF) or cell tracker violet (Invitro-
gen) as reported earlier (Massberg et al., 2002). The DCF-labeled platelet 
suspension was adjusted to a final concentration of 150 × 106 platelets/250 µl 
and injected i.v. via a jugular vein catheter. For in vivo staining, a nonblock-
ing  GPIb-binding  fluorescent-labeled  antibody  (3  µg/animal;  rat  anti–
mouse DyLight488-labeled GPIb antibody; Emfret Analytics) was infused 
i.v. Adhesion and aggregation of murine platelets were assessed by in vivo 
whether neutrophils and NETs also contribute to DVT in 
settings where venous stasis is not the primary trigger of throm-
bogenesis, e.g., in cancer or sepsis patients.
Because negatively charged surfaces (as the ones provided 
by NETs) are a major trigger of FXII activation (Griep et al., 
1985), we evaluated here whether activation of the contact 
pathway might contribute to the prothrombotic actions of 
NETs. In fact, we found that NETs bind and activate FXII 
in vitro. In addition, inhibition or genetic ablation of FXII pro-
vided protection against DVT propagation, suggesting that 
FXIIa contributes to the prothrombotic potential of NETs. 
Consistent with previous observations in arterial thrombosis 
(Cheng et al., 2010), FXI deficiency only had a minor impact 
on venous thrombogenesis. This indicates that FXIIa con-
tributes  to  venous  thrombogenesis  predominantly  using 
FXI-independent pathways, e.g., via a direct stabilization of 
the fibrin network (Konings et al., 2011).
Together, our study identifies NETs as a platform of 
thrombogenesis in large veins in response to perturbation of 
flow. We observed that mice deficient in blood cell TF have 
no thrombi, whereas neutropenia or loss of FXII results in a 
decreased thrombus weight but does not fully protect from 
DVT formation. This suggests that blood cell TF is required to 
initiate DVT, whereas neutrophil-driven coagulation, includ-
ing activation of FXII, contributes to DVT propagation and 
stabilization in settings of compromised venous blood flow.
One of the most intriguing findings reported here is that 
platelets, the major players of arterial thrombosis, also contrib-
ute to the propagation of DVT in the absence of endothelial 
disruption. In fact, we found that platelets are recruited to de-
veloping venous thrombi early after flow restriction and con-
tribute to DVT formation by supporting accumulation of 
innate immune cells and by binding to leukocytes, a process 
which initiates NET formation both in vitro and in vivo. 
GPIb was essential for platelet-driven propagation of DVT, 
as it was required for both platelet accumulation in the throm-
bus and, particularly, for platelet–leukocyte interactions, which 
in turn augment the ability of neutrophils to release procoagu-
lant NETs. Hence, platelets induce sterile inflammation and 
foster venous clot formation by cooperating with netting neu-
trophils. The critical role of platelets in DVT formation is fur-
ther supported by the importance of vWF in DVT and by the 
clinical observation that the anti-platelet drug aspirin is pro-
phylactic against venous thrombosis in high-risk patients under-
going orthopedic surgery, a condition frequently associated 
with compromised venous blood flow (PEP-Group, 2000; 
Brill et al., 2011). It should be mentioned, though, that the 
contribution of platelets to DVT might be different in settings 
where stasis is not the primary trigger.
In conclusion, our study shows that DVT in response to 
perturbed blood flow is driven by a concerted interaction of 
monocytes, netting neutrophils, and platelets and thus un-
covers  the  mechanisms  linking  inflammation  and  venous 
thrombosis. Disruption of this cooperation and prevention of 
monocyte- and neutrophil-driven thrombogenesis paves the 
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was confirmed by a white blood cell count (Sysmex) of EDTA whole blood 
and by intravital video microscopy using LysM-eGFP mice. Platelet deple-
tion was induced using the rat anti–mouse GPIb (CD42b) antibody i.v. 
(2 mg/kg body weight; Emfret Analytics).
FXII inhibitor and enoxaparin treatment. C57BL/6J mice were treated 
with  FXII  inhibitor  (H-D-Pro-Phe-Arg-chloromethylketone;  10  mg/kg 
body weight i.v.; Bachem) directly before stasis and then every 24 h. Enoxa-
parin was administered s.c. 3 h before and every 6 h after ligation in a dosage 
of 60 mg/kg body weight and FXa was monitored.
Histology. The IVC was excised, formalin fixed, and paraffin embedded. 
Serial cross sections or longitudinal sections of the ligated IVC were cut 
(2 µm) 6 and 48 h after flow reduction. Tissue sections were stained with 
HE, van Gieson’s elastica stain, and MSB (Martius scarlet blue). Images were 
acquired using an epifluorescence microscope (DMRB; Leica) with an 
AxioCam  (Carl  Zeiss)  and  processed  by  AxioVision  4.6  software  (Carl 
Zeiss). Where indicated, the thrombus load, a parameter which like the 
thrombus weight accounts for the size of the thrombus, was measured on 
serial cross sections by circling the outer edge of the luminal thrombus tissue 
in sections from the proximal, middle, and distal part of the IVC (Cap-Image 
7.1). For Carstairs staining, slides were hydrated in xylol and ethanol to dis-
tilled water, followed by incubation in 5% ferric ammonium sulfate for 
5 min and staining by Mayer hematoxylin for 5 min and Picric Acid-orange 
G solution for 45 min. After washing, slides were stained by Ponceau Fuch-
sin solution for 3 min, 1% phosphotungstic acid for 3–5 min, Anilin blue   
solution for 10 min, and rinsed in distilled water. Slides were dehydrated 
covered with a coverslip using mounting medium (Pertex). All reagents 
were provided by EMS. Fibrin density was quantified by ImageJ as the 
fibrin-positive area of the total thrombus area (percentage). Lungs were ex-
cised 48 h after DVT induction, formalin fixed, and paraffin embedded. 
Sections of 3 µm thickness were cut systematically of the whole lung to 
screen for signs of pulmonary embolism in HE staining.
Immunofluorescence stainings of frozen sections. For immunofluor-
escence staining of frozen sections, the excised vessel was immediately 
rinsed with PBS, embedded in OCT, and frozen at 80°C. The IVC was 
cut with a cryotome into sections of 5 µm thickness. Specimens were fixed 
with 4% formalin for 4 min, washed in PBS, and blocked with 5 µg/ml 
anti–mouse CD16/32 (eBioscience) and 1% BSA (PAA Laboratories) in PBS 
for 30 min. The sections were incubated with primary antibodies (Table S1) 
for 1 h at room temperature and washed in PBS + 0.1% Tween. Next, sec-
ondary antibodies (Table S1) were used for detection. For double staining, a 
sequential protocol was performed. DNA was stained with 1 µg/ml Hoechst 
33342 (Invitrogen) or 1 µg/ml DAPI (Roth), and a coverslip was placed by 
mounting medium (DAKO). Images were acquired using an epifluorescence 
microscope (DMRB) with an AxioCam and processed by AxioVision 4.6 
software or a two-photon microscope (TrimScope) and Volocity (Perkin-
Elmer) as indicated. For quantification of NETs, serial cross sections were 
stained with Hoechst and the number of NETs was counted with a 40× ob-
jective in four fields of view (176 × 131 µm). The sections originated from 
the proximal, middle, and distal part of the IVC. For quantification of NET 
formation,  three  distinct  parameters  had  to  be  met  in  our  experiments:   
(1) presence of extracellular DNA protrusions; (2) the protrusion had to 
originate from cells staining positive for neutrophil markers; and (3) the 
structures had to be decorated with markers of neutrophil granule proteins 
including NE or MPO. Only if all of these criteria were fulfilled was a 
structure defined as NET and included into the quantification.
Computed tomography. Anaesthetized mice were imaged with the In-
veon small animal PET/CT scanner (Siemens). Mice were kept fully sedated 
with 1.5% isoflurane during injections and imaging. To obtain vascular con-
trast, 0.1 ml of iodinated intravascular contrast agent eXIA 160-XL (Binitio 
Biomedical Inc.) was injected i.v. CT acquisition consisted of 270 projec-
tions acquired with exposure time of 400 ms, x-ray voltage of 80 kVp, and 
video microscopy. For the qualification and quantification of leukocyte ad-
hesion, rhodamine 6G (Invitrogen) or Acridine orange (Sigma-Aldrich) was 
injected i.v. to stain circulating leukocytes in vivo. To characterize platelet-
leukocyte interactions in vivo, Acridine orange–stained leukocytes and 
ex vivo labeled platelets (20 µg/ml rhodamine B; Sigma-Aldrich) were im-
aged simultaneously. To differentiate neutrophils and monocytes, LysM-
eGFP and CX3CR1-eGFP mice were used. The ratio of these cell types in 
relation to the total number of recruited leukocytes was analyzed by first 
taking images of the eGFP-labeled cells, followed by injection of Acridine 
orange to visualize all leukocytes. Detection of extracellular DNA (NET 
formation) in vivo was achieved by i.v. infusion of Sytox green or orange 
after flow reduction (1 µmol per animal).
Assessment of fibrin formation in vivo. Fibrin formation in vivo was 
measured in HCV and Low-hTF using an Alexa Flour 488 (Invitrogen) 
ex vivo labeled anti-fibrin antibody (2 mg/kg body weight, mouse anti-fibrin 
II chain B 15–42, clone T2G1; Accurate Chemical) which was injected 
i.v. This antibody specifically binds to fibrin formed in the vascular system. 
Fluorescence intensity was quantified by intravital video microscopy (BX51WI; 
Olympus). Fibrin formation is presented as mean fluorescence intensity 
(arbitrary units).
Intravital epifluorescence microscopy. The mice were anesthetized as 
described, the flow restricting procedure was performed, and the animals were 
fixed on a custom built-stage to maintain a physiological temperature. Mea-
surements were performed with a high-speed wide-field Olympus BX51WI 
fluorescence microscope using a long-distance condenser and a 20× (NA 0.95) 
water immersion objective with a monochromator (MT 20; Olympus) and a 
charge-coupled device camera (ORCA-ER; Hamamatsu Photonics). For 
image acquisition and analysis a computer (Dell) with Cell^R (Olympus) soft-
ware was used. Cell recruitment was quantified in four fields of view (50 × 
100 µm) per animal; immotile cells were counted as adherent and moving cells 
were counted as rolling within 30 s as previously described (Massberg et al., 
1998). The cell covered area (in square millimeters) and colocalization area was 
determined by planimetric measurement (Cap-Image 7.1).
Two-photon in vivo microscopy. For intravital imaging of the IVC   
in vivo, the TrimScope (LaVision Biotech) connected to an upright microscope 
(Olympus) was used, equipped with a MaiTai laser (Spectra-Physics) and a 
20× 0.95 NA water immersion objective (Olympus). Pictures were acquired 
at 800 nm excitation wavelength in a 500 × 500-µm frame with 512 × 512 
pixels and a z-step of 3 µm and detected by PMTs (G6780-20, Hamamatsu). 
ImSpector (LaVision Biotech) was used as acquisition software. The mice 
were anesthetized as described, the flow restricting procedure was performed, 
and the animals were fixed on a custom-built stage to maintain a physiological 
temperature. LysM-eGFP mice, CX3CR1-eGFP mice, and an FITC- or PE-
labeled anti-Ly6G antibody (10 µg/animal; Clone 1A8; eBioscience) were 
used to visualize neutrophils and monocytes. In addition, cell tracker violet 
(Invitrogen)–labeled platelets and 2 MD TRITC-Dextran (Invitrogen) for 
visualization of the blood flow were infused. 3D reconstruction and volume 
rendering was done with by Volocity (PerkinElmer) and cell tracking with 
ImageJ software (National Institutes of Health).
Bone marrow transplantation. For generation of bone marrow chimeras, 3 × 
106 bone marrow cells of Low-hTF mice were injected into the tail vein of irradi-
ated (900 rad) HCV (hTF) mice. 6 wk after transplantation, when a stabile chi-
merism is guaranteed, thrombus formation was induced in the IVC and intravital 
video microscopy was performed (as described in the previous sections).
Inhibition of NETosis and depletion of neutrophils and platelets   
in vivo. DNase1 (100 U DNase1, RNase-free; Fermentas) was given i.v. 
30 min before and 24 h after IVC ligation by tail vein injection, and normal 
saline injection served as control. Neutrophils were depleted by an anti-Ly6G 
antibody (5 mg/kg body weight; rat anti-mouse Ly6G, Clone 1A8; eBiosci-
ence) given i.v. 24 h before induction of thrombosis. The absence of neutrophils JEM Vol. 209, No. 4 
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A 63× magnification was obtained with the use of Plan-Apochromat lenses 
(1.4 NA, oil immersion). Image acquisition was performed using LSM 
Browser software (Carl Zeiss), and for the image processing Photoshop 
(Adobe) was used.
Factor XIIa formation assay. Neutrophils (N) were only preactivated 
with 100 nM PMA (control) or co-incubated with platelets (P/N) for 15 min 
at 37°C in the presence of 8 µg/ml collagen. Subsequently, they were incu-
bated for 30 min with H2A-H2B-DNA–specific antibody or control IgG 
(each 20 µg/ml). Then the samples were mixed with 50 nM FXII in the 
presence of 50 µM ZnCl2 and a chromogenic substrate S2302. The absorp-
tion of the samples was measured photometrically at 405 nm. FXII in 50 µM 
ZnCl2 and S2302 (Co), preactivated platelets alone (P), and preactivated 
neutrophils alone (N) served as controls
RT-PCR. RNA was isolated from the whole IVC using the NucleoSpin 
RNA XS kit (Macherey-Nagel) according to the manufacturer’s instruc-
tions. Template cDNA was synthesized from 2 µg total RNA using the High 
Capacity cDNA Archive kit (Applied Biosystems) and applied in SYBR 
Green assays performed on a GeneAmp 7700 Sequence Detection System 
(Applied Biosystems). The murine sequences of CXCL1, CXCL5, CCL2, 
IL6, and P-selectin were detected by QuantiTect Primer Assays (QIAGEN). 
Cycling conditions were 50°C for 2 min and 95°C for 15 min, followed by 
40 cycles of denaturation at 95°C for 15 s, and annealing and elongation at 
60°C for 60 s. Gene expression ratios for each sample (regulation factors and 
standard  deviation)  were  calculated  using  the  ddCt  method  (Livak  and 
Schmittgen, 2001) and normalized against -actin. Experiments were per-
formed as triplicate, including non-reverse transcription and nontemplate 
controls. Dissociation analysis confirmed the specificity of the reaction.
FACS. Whole blood from each animal was collected from the facial vein 
and assayed for flow cytometry by standard techniques. Neutrophils were 
stained using PE-labeled rat anti–mouse Ly6G (clone 1A8; BD), and mono-
cytes were detected by double-positive staining with rat anti–mouse CD115-
PE (clone AFS98; eBioscience) and rat anti–mouse CD11b-APC (clone 
M1/70; eBioscience). Antibody specificity was verified using an appropriate 
isotype-labeled antibody (anti–rat IgG2a or anti–rat IgG2b). Erythrocytes 
were depleted from the preparations with BD FACS lysing solution (BD). 
Flow cytometric measurement was performed on a FACSCalibur (BD) 
using CellQuest software.
Statistical analysis. All data are shown as mean ± SEM, unless indicated 
otherwise. Thrombus weight was tested for normal distribution using the 
Kolmogorov-Smirnov test and the independent samples Student’s t test was 
performed to compare groups (SPSS). More than two groups were com-
pared using the ANOVA-LSD post hoc test. Parameters like number of ad-
herent cells/mm2 or aggregation area were analyzed by unpaired Student’s   
t test. For flow velocity data, the paired Students t test was used. A value 
of P < 0.05 was considered significant.
Online supplemental material. Video 1 shows an i.v. contrast-enhanced 
computed tomography image of a thrombosed IVC in vivo. Video 2 illus-
trates the recruitment of leukocytes to the IVC. Video 3 shows crawling 
neutrophils on the venous vessel wall. Video 4 visualizes the recruitment of 
neutrophils in LysM-eGFP mice to the endothelium. Video 5 shows mono-
cytes and neutrophils in CX3CR1-eGFP mice attached to the vessel wall. 
Video 6 demonstrates the 3D structure of NETs in the thrombus. Video 7 is 
a time-lapse movie demonstrating extracellular DNA originating from neu-
trophils in vivo inside the IVC. Video 8 is a time-lapse movie showing 
platelets and neutrophils forming a thrombus at the vessel wall. Video 9 
illustrates in 3D how neutrophils and platelets cover the endothelial surface 
in vivo. Video 10 shows how platelets recruit neutrophils to the developing 
thrombus in a time-lapse movie. Table S1 lists the antibodies used for the 
experiments. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20112322/DC1
anode current of 400 µA for a full 360° rotation. CT images were reconstructed 
using a modified Feldkamp algorithm. The resulting matrix was 256 × 256 
pixels with 384 transverse slices (pixel size 0.17 × 0.17 × 0.17 mm).
Scanning and transmission electron microscopy. Mice were sacrificed 
and the IVC was perfused with 3 ml PBS (37°C) in C57BL/6, followed by 
perfusion fixation with 1% phosphate-buffered glutaraldehyde. The vein was 
carefully dissected and cut open longitudinally, further fixed by immersion in 
1% PBS-buffered glutaraldehyde for 12 h, dehydrated in ethanol, and pro-
cessed by critical point drying with CO2. Thereafter, the veins were oriented 
with the lumen exposed, mounted with carbon paint, sputter coated with 
platinum, and examined using a field emission scanning electron microscope 
(JSM-6300F; Jeol Ltd; Massberg et al., 2003). The transmission electron 
microscopy was performed to characterize the ultrastructure of the venous vessel 
wall and the generated venous thrombi. The IVC of C57BL/6 mice was per-
fused with 3 ml PBS (37°C) and perfusion fixed in a solution consisting of 
2.5% buffered glutaraldehyde and 2% paraformaldehyde in phosphate buffer, 
pH 7.4, overnight at 4°C. The specimens were mounted in epon solution 
and sections of 50–100 nm were prepared with an ultra microtome.
Confocal microscopy of NETs in vitro. For preparation of human neu-
trophils, blood was drawn from healthy donors into syringes containing Tri-
natrium citrat (1:10). Whole blood was added to dextran 3% (MW 500,000; 
2:1) and inverted before red blood cells were allowed to separate for 30 min 
at room temperature. Thereafter, the supernatant was removed, layered on 
top of Ficoll (1:1), and centrifuged for 30 min at room temperature at 
1,200 rpm. The supernatant was removed and the pellet was resuspended in 
RPMI/10 mM Hepes. Cells were centrifuged for 10 min at room tempera-
ture at 1,000 rpm. To lyse residual blood cells, the pellet was resuspended in 
1 ml pyrogen-free water (ultrapure) and, after addition of RPMI/10 mM 
Hepes, centrifuged for 10 min at room temperature at 1,000 rpm. The pellet 
was resuspended in RPMI/10 mM Hepes.
Preparation of platelet supernatant. Platelets were isolated as described 
elsewhere (Massberg et al., 2010). 109 platelets were activated with 8 µg/ml 
collagen and 0.1 U/ml thrombin for 30 min at 37°C. Subsequently, cells were 
centrifuged at 12,600 rpm for 30 min and the supernatant was collected. Freshly 
isolated human neutrophils were plated at 105 on poly-l-lysine–coated Fluoro-
Dishes and incubated for 15 min at 37°C with platelets in the presence of 
100 nM PMA and 20 µg/ml aprotinin. Short-term incubation with PMA 
does not lead to NET formation.
Thereafter, cells were fixed with 4% PFA in PBS. Cells were washed 
three times with PBS and then incubated with blocking buffer (5% fish gela-
tin, 5% donkey serum, 1% BSA, and 0.05% Tween 20 in PBS, pH 7.4) for 
30 min at 37°C. Cells were stained with a primary antibody directed against 
H2A-H2B-DNA complexes (1:10 in blocking buffer), which was generated 
as previously described (Losman et al., 1992), for 30 min at 37°C. Cells were 
washed three times with PBS before applying a secondary antibody goat 
anti–mouse Cy3-labeled (1:300 in blocking buffer) for 2 h at 37°C (Invitro-
gen). Cells were washed three times with PBS and two times with aqua dest. 
before an incubation with DAPI (Sigma-Aldrich) to detect DNA. Cells were 
washed two times with aqua dest. before microscopic analysis, and the sam-
ples were pretreated with 10 U/ml DNase1 or vehicle as control.
For visualization of colocalization of NETs and FXII, human neutrophils 
were plated at 5 × 104 on poly-l-lysine–coated FluoroDishes. After 30 min of 
co-incubation with 5 × 105 platelets in the presence of 100 nM PMA and 
20 µg/ml aprotinin in Hepes buffer, 100 nmol FXII was added for additional 
15 min at 37°C in the presence of zinc. The negative control did not contain 
FXII. Then cells were fixed in 4% PFA, and the nucleic acids were stained by 
Sytox green (Invitrogen) as described in the manual. The nonspecific bindings 
were blocked, and afterward 5 mg/ml of a mouse anti–human FXII antibody 
(ab1007; Abcam) was added for 1 h, followed by a secondary anti–mouse 
Alexa Fluor 594 (Invitrogen) antibody for 30 min at 2 mg/ml in PBS.
Visualization was performed by confocal microscopy using an LSM 510 
META (Carl Zeiss), based on an inverted Axiovert 200 MOT microscope. 834 Innate immune cells and platelets initiate DVT | von Brühl et al.
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